ANNUAL DIRECT AND INDIRECT COSTS OF US EMPLOYEES WITH BIPOLAR DISORDER, SCHIZOPHRENIA AND CONTROLS FROM 2001 TO 2011

Richard Brook, MS, MBA; Kirthika Rajagopal, PhD; Nathan Kleinman, PhD; Mariam Hassan, PhD; Jacob Young; Jim Smeeding, MBA, RPh; Andrei Pikulak, MD, PhD

1. JASTARx Group, Newfoundland, NJ; 2. Sunovion Pharmaceuticals, Fort Lee, NJ and Marlborough, MA; 3. HCMS Group, Cheshire, WY

ABSTRACT

Study Objectives: To compare the annual direct and indirect costs between US employees with Bipolar Disorder (BPD), Schizophrenia, and Controls from 2001 to 2011. Methodology: Retrospective analysis of administrative data and employee payroll data for BPD and Schizophrenia subjects, as well as a comparison control group. The data were obtained from a large, multi-employer study. The description statistics for the different variables were calculated for each group and described in tabular and graphical form. The annual costs of health care, disability, and productivity losses were compared. RESULTS: The annual costs for the study cohorts were as follows: BPD: $8,375; Schizophrenia: $8,812; Controls: $4,263. CONCLUSIONS: The study found that employees with BPD and Schizophrenia had significantly higher annual health care costs compared to Controls. The results highlight the economic burden of these disorders on employers.

METHODS

1. Data collection: Data were collected from a multi-employer study that included 30 United States employers. 2. Data analysis: The data were analyzed using descriptive statistics and regression models to compare the costs between the study cohorts. 3. Results: The annual costs for the study cohorts were as follows: BPD: $8,375; Schizophrenia: $8,812; Controls: $4,263. 4. Conclusions: The study found that employees with BPD and Schizophrenia had significantly higher annual health care costs compared to Controls. The results highlight the economic burden of these disorders on employers.

RESULTS

1. The annual costs for the study cohorts were as follows: BPD: $8,375; Schizophrenia: $8,812; Controls: $4,263. 2. The regression models showed that employees with BPD and Schizophrenia had significantly higher annual health care costs compared to Controls. 3. The results highlight the economic burden of these disorders on employers.

DISCUSSIONS

1. The study found that employees with BPD and Schizophrenia had significantly higher annual health care costs compared to Controls. 2. The results highlight the economic burden of these disorders on employers.

REFERENCES


LIMITATIONS

1. The study is based on self-reporting data. 2. The results may not be generalizable to all employers and workers. 3. The study was conducted in the United States.

CONCLUSIONS

1. The study found that employees with BPD and Schizophrenia had significantly higher annual health care costs compared to Controls. 2. The results highlight the economic burden of these disorders on employers.

DISCLOSURES


Sponsored by Sunovion Pharmaceuticals Inc.